November 04, 2005 10:20 ET

Nymox Files Further Proposals with FDA about Alzheimer Test Kit

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Nov 4, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it has filed further proposals with the FDA concerning meeting requirements for approval of the Company's PMA for its proprietary urine NTP test kit. The urine NTP test kit is based on the Company's AlzheimAlert™ testing technology which provides a valuable aid to physicians in the diagnosis of Alzheimer's disease.

The urine NTP test kit is currently available in Europe as a result of certification with the CE Mark. The Company recently announced distribution and marketing agreements for the urine NTP test kit in Italy, Spain, Greece and the Czech Republic. In the U.S. the Company offers AlzheimAlert™ to physicians through its CLIA-certified clinical reference laboratory in New Jersey. The Company has applied for approval from FDA to sell the urine NTP test kit to laboratories and hospitals in the U.S.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure. Nymox offers AlzheimAlert™, a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX